Compare RF & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RF | WST |
|---|---|---|
| Founded | 1970 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 17.9B |
| IPO Year | N/A | 2004 |
| Metric | RF | WST |
|---|---|---|
| Price | $26.34 | $253.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 7 |
| Target Price | $29.30 | ★ $319.43 |
| AVG Volume (30 Days) | ★ 13.5M | 788.3K |
| Earning Date | 04-17-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.06% | 0.35% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 6.79 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $15.11 | $6.76 |
| Revenue Next Year | $3.72 | $6.15 |
| P/E Ratio | ★ $13.07 | $36.97 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $17.74 | $187.43 |
| 52 Week High | $31.53 | $322.34 |
| Indicator | RF | WST |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 58.70 |
| Support Level | $23.71 | $239.86 |
| Resistance Level | $26.77 | $261.98 |
| Average True Range (ATR) | 0.58 | 7.05 |
| MACD | 0.17 | 1.56 |
| Stochastic Oscillator | 88.86 | 91.95 |
Regions Financial is one of the midsized regional banks in the US, with around $160 billion in total assets as of Sept. 30, 2025. Headquartered in Birmingham, Alabama, Regions Financial has a footprint mostly in the US southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, wealth management, and capital markets.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.